Bioequivalence of Oxazepam 10 mg Orodispersible Tablets Versus Seresta® 10 mg Tablets in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- o medical condition is being investigated. This is a comparative bioavailabilty study.MedDRA version: 20.0Level: PTClassification code: 10002855Term: Anxiety Class: 100000004873MedDRA version: 20.0Level: PTClassification code: 10012225Term: Delirium tremens Class: 100000004873Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2022-501134-35-00
- Lead Sponsor
- aboratorios Lesvi S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Oxazepam's action in treating anxiety and delirium tremens?
How does the orodispersible formulation of Oxazepam compare to traditional tablets in terms of bioavailability and patient compliance?
What biomarkers are associated with response to Oxazepam in nervous system disorders like anxiety and delirium tremens?
What adverse events are commonly reported with Oxazepam and how do they compare to other benzodiazepines like Seresta®?
Are there any combination therapies involving Oxazepam that show improved efficacy for anxiety-related conditions?